MX2024000268A - Composiciones farmaceuticas de un anticuerpo contra pd-1 y uso de las mismas. - Google Patents

Composiciones farmaceuticas de un anticuerpo contra pd-1 y uso de las mismas.

Info

Publication number
MX2024000268A
MX2024000268A MX2024000268A MX2024000268A MX2024000268A MX 2024000268 A MX2024000268 A MX 2024000268A MX 2024000268 A MX2024000268 A MX 2024000268A MX 2024000268 A MX2024000268 A MX 2024000268A MX 2024000268 A MX2024000268 A MX 2024000268A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
antibody
same
retifanlimab
containers
Prior art date
Application number
MX2024000268A
Other languages
English (en)
Spanish (es)
Inventor
Yan Zhou
Stephen James Burke
Krishnan Sampathkumar
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of MX2024000268A publication Critical patent/MX2024000268A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MX2024000268A 2021-07-09 2022-06-22 Composiciones farmaceuticas de un anticuerpo contra pd-1 y uso de las mismas. MX2024000268A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163220006P 2021-07-09 2021-07-09
PCT/US2022/034493 WO2023283049A1 (en) 2021-07-09 2022-06-22 Pharmaceutical compositions of a pd-1 antibody and use of the same

Publications (1)

Publication Number Publication Date
MX2024000268A true MX2024000268A (es) 2024-01-31

Family

ID=82608118

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024000268A MX2024000268A (es) 2021-07-09 2022-06-22 Composiciones farmaceuticas de un anticuerpo contra pd-1 y uso de las mismas.

Country Status (17)

Country Link
US (2) US12364756B2 (cg-RX-API-DMAC10.html)
EP (1) EP4366692A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024525566A (cg-RX-API-DMAC10.html)
KR (1) KR20240035533A (cg-RX-API-DMAC10.html)
CN (1) CN118215465A (cg-RX-API-DMAC10.html)
AR (1) AR126404A1 (cg-RX-API-DMAC10.html)
AU (1) AU2022307332A1 (cg-RX-API-DMAC10.html)
CA (1) CA3224640A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024000077A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024000198A2 (cg-RX-API-DMAC10.html)
CR (1) CR20240065A (cg-RX-API-DMAC10.html)
EC (1) ECSP24008791A (cg-RX-API-DMAC10.html)
IL (1) IL309985A (cg-RX-API-DMAC10.html)
MX (1) MX2024000268A (cg-RX-API-DMAC10.html)
PE (1) PE20240797A1 (cg-RX-API-DMAC10.html)
TW (1) TW202308694A (cg-RX-API-DMAC10.html)
WO (1) WO2023283049A1 (cg-RX-API-DMAC10.html)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2476934C (en) * 2002-02-27 2009-06-16 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
PE20231958A1 (es) * 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3705134A4 (en) * 2017-11-02 2021-07-28 Nanjing Shunxin Pharmaceutical Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING A HUMANIZED MONOCLONAL ANTIBODY ANTI-PD-L1
IL277095B2 (en) * 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
CN110404066B (zh) * 2018-04-28 2022-06-17 齐鲁制药有限公司 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
WO2021022172A1 (en) 2019-08-01 2021-02-04 Incyte Corporation A dosing regimen for an ido inhibitor
CN114206386A (zh) 2019-08-05 2022-03-18 小野药品工业株式会社 免疫检查点抑制剂的有效性判定生物标记

Also Published As

Publication number Publication date
KR20240035533A (ko) 2024-03-15
JP2024525566A (ja) 2024-07-12
PE20240797A1 (es) 2024-04-18
CA3224640A1 (en) 2023-01-12
US20230025464A1 (en) 2023-01-26
AR126404A1 (es) 2023-10-11
EP4366692A1 (en) 2024-05-15
CR20240065A (es) 2024-04-08
TW202308694A (zh) 2023-03-01
AU2022307332A1 (en) 2024-01-18
US20250345422A1 (en) 2025-11-13
WO2023283049A1 (en) 2023-01-12
IL309985A (en) 2024-03-01
ECSP24008791A (es) 2024-03-01
US12364756B2 (en) 2025-07-22
CN118215465A (zh) 2024-06-18
CO2024000198A2 (es) 2024-02-05
CL2024000077A1 (es) 2024-08-23

Similar Documents

Publication Publication Date Title
CR20220614A (es) 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cáncer
Herrera et al. A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease
MX2022014332A (es) Conjugado anticuerpo-farmaco, metodo de preparacion del mismo y uso del mismo.
MX2023009971A (es) Composicion farmaceutica que contiene anticuerpo anti-tslp.
PL1673063T3 (pl) Transdermalna kompozycja farmaceutyczna
MA64856B1 (fr) Formes de dosage solides et regimens de dosage comprenant le [[3-(3,4-difluoro-2-méthoxy-phényl)-4,5-diméthyl-5-(trifluorométhyl) tétrahydrofuranne-2-carbonyl]amino]pyridine-2-carboxamide
Unnanuntana et al. The effects of farnesol on Staphylococcus aureus biofilms and osteoblasts: an in vitro study
Ayas et al. Factors affecting the outcome of related allogeneic hematopoietic cell transplantation in patients with Fanconi anemia
MX2024015058A (es) Terapia combinada de agente activo anti proteína de muerte programada 1 (pd-1), agente activo anti dominio 3 de inmunoglobulina y mucina de linfocitos t (tim-3) y agente activo anti gen 3 de activación de linfocitos (lag-3) para tratar el cáncer
WO2025019819A3 (en) Small molecule protein degraders of kras g12d mutant
SE8700467L (sv) Monoklonala humanantikroppberedningar som er korsprotektiva
CR20240065A (es) Composiciones farmacéuticas de un anticuerpo contra pd-1 y uso de las mismas
MX2024007749A (es) Formulaciones clinicas de anticuerpos anti-tigit.
MX2024000690A (es) Composiciones farmaceuticas de un anticuerpo b7-h3 y uso de las mismas.
MX2023006383A (es) Composicion farmaceutica que contiene anticuerpo anti-factor de crecimiento de tejido conjuntivo.
PH12018501508A1 (en) Depilatory compositions
AU749923C (en) The use of combinations of active agents consisting of antimicrobially active substances and plant extracts containing terpene in veterinary medicine
CA2384418C (en) Use of cytokines, cells, and mitogens to inhibit graft versus host disease
Fehniger et al. A phase 2 multicenter study of continuous dose lenalidomide in relapsed or refractory classical Hodgkin lymphoma
PL431336A1 (pl) Lipopeptydy, kompozycja farmaceutyczna, kompozycja kosmetyczna oraz lipopeptydy do zastosowania jako lek
NO20033555D0 (no) Sammensetning av östrogen og andre hormoner med askorbatlysin, prolin og andre stoffer
Colli et al. Staphylococcus lugdunensis and Trichophyton tonsurans infection in synthetic hair implants
WO2022165275A8 (en) Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
WO2020175922A3 (ko) 고혈압 및 고지혈증을 치료 또는 예방하기 위한 단일 제형의 약학 조성물
Rosen et al. Management algorithms for dermatologic adverse events